KURA
Kura Oncology, Inc. Health Care Pharmaceutical Preparations Russell 3000
$10.26Close
$901.4MMarket cap
$7.40 – $13.5952-week range
Nov 3, 2026Next report
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Results soon Nov 3, 2026, in 2 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
25%
1wk
up 6.8%
price change
1mo
down 4.2%
price change
12-month return
down 2%
market up 11% ·
its own down 11%
F-score
—
— Not assessed
Altman Z
-1.57
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
5.2×
price / book
Earnings yield
down 39.8%
EBIT / enterprise value
Cheaper than
15%
of the market · expensive
Revenue growth
up 25%
year on year
EPS growth
—
latest quarter
Sales growth
up 37%
latest quarter · +7 pts
ROE
down 95%
return on equity
Free cash margin
down 105%
-$70.7M FCF
D/E
0.06
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.3%
$0.54 a day · 2×ATR $9.18
RS
69 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
1.2×
vs 50-day average
Up/down volume
0.81
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 12.3% over the year, from 78m to 88m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 12, 2026
Results reaction
Aug 12, 2026+1% vs market2 sessions after results
Financials
- Net -413%
- Free cash -105%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $53.9M | $67.5M |
| Operating income | — | — | -$139.9M | -$165.8M | -$193.2M | -$303.6M |
| Net income | -$89.6M | -$130.5M | -$135.8M | -$152.6M | -$174.0M | -$278.7M |
| Net margin | — | — | — | — | -323% | -413% |
| Earnings per share | -$1.69 | -$1.97 | -$2.03 | -$2.08 | -$2.02 | -$3.18 |
| Free cash flow | -$72.0M | -$105.7M | -$110.7M | -$125.0M | $133.8M | -$70.7M |
| Free cash margin | — | — | — | — | 248% | -105% |
| Cash | $325.5M | $90.7M | $51.8M | $37.3M | $224.5M | $149.1M |
| Long-term debt | $4.2M | — | $9.2M | $9.3M | $6.9M | $9.7M |
| Shareholders' equity | $610.9M | $506.6M | $420.3M | $397.3M | $413.6M | $174.1M |
| Shares outstanding | 66.19m | 66.57m | 68.31m | 74.35m | 78.23m | 87.86m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 12, 2026 | Quarterly ↗ | Jun 30, 2026 | 43d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 5, 2026 | Annual ↗ | Dec 31, 2025 | 64d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 9, 2026 | Other events ↗ |
| Sep 8, 2026 | Director or officer change ↗ |
| Aug 12, 2026 | Results ↗ |
| Jul 29, 2026 | Director or officer change ↗ |
| Jun 4, 2026 | Director or officer change · Shareholder vote ↗ |
| May 12, 2026 | Results ↗ |
| Mar 5, 2026 | Results ↗ |
| Jan 29, 2026 | Charter or bylaws ↗ |
| Jan 12, 2026 | Results ↗ |
| Dec 2, 2025 | Other events ↗ |
| Nov 13, 2025 | Other events ↗ |
| Nov 4, 2025 | Results ↗ |